Principal Investigator

Jeremy L. Davis, MD

Leading the Precancer Genomics Lab is Dr. Jeremy L. Davis, a surgical oncologist, Professor and Chief of Surgical Oncology at University of Maryland School of Medicine. Prior to the faculty, Dr. Davis was a clinical investigator at the National Cancer Institute in Bethesda, Maryland. 

Dr. Davis's research has focused on the molecular underpinnings of CDH1-driven diffuse-type gastric cancers, endoscopic surveillance as an alternative to prophylactic gastrectomy, and the long-term impact of surgery on the prevention of cancers.

The Precancer Genomics Lab is dedicated to understanding cancer at its earliest stages, even before it fully develops. Our research delves into the intricate genomic landscape of precancerous cells and their microenvironment, seeking to identify vulnerabilities and unlock strategies for early intervention and, ultimately, a future with less cancer.

Key Research Areas

Decoding Individual Cancer Risk

We investigate CDH1, CTNNA1 and other germline genetic predisposition syndromes and the earliest genomic changes that generate susceptibility to gastric, breast and other cancers.

The Microenvironment's Fingerprint on Precancer

Our research explores how tissue and host-specific factors interact with precancers to either promote or protect against the progression of premalignant cells.

Targeting Precancer

Developing Tomorrow's Preventative Therapies: We aim to identify specific genomic alterations in precancerous cells that can be targeted with innovative therapies to halt or even reverse their progression towards cancer.
 

Research Resident (2025-2027)

Rachael Belcher

 

Previous Lab Members

Cassidy Bowden

Amber Gallanis

Lauren Gamble

Sarah Samaranayake

We're Hiring!

Join a collaborative team using cutting-edge models and patient-derived resources to make discoveries with real clinical impact. Ready to make a difference?

Connect with us today